An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This extended access study will assess the long-term safety and tolerability of bardoxolone
methyl in qualified patients with chronic kidney disease (CKD) who previously participated in
one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the
study until bardoxolone methyl is available through commercial channels or until patient
withdrawal, whichever is sooner.